The Asia Pacific PARP Inhibitor Biomarkers Market would witness market growth of 8.9% CAGR during the forecast period (2024-2031).
The China market dominated the Asia Pacific PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $109.1 Million by 2031. The Japan market is registering a CAGR of 8.2% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 9.6% during (2024 - 2031).
The adoption of this in clinical practice and research settings has been steadily increasing, driven by several factors that highlight their importance in personalized cancer care and precision medicine. For example, clinical practice guidelines from reputable organizations, such as the National Comprehensive Cancer Network (NCCN).
Additionally, the market is witnessing several notable trends that reflect the evolving landscape of precision oncology and personalized cancer care. These trends encompass advancements in biomarker discovery, technological innovations in biomarker testing, shifts in clinical practice guidelines, and the emergence of novel therapeutic strategies.
As the hospital sector in India expands, there is increased access to healthcare services, including diagnostic facilities and specialized testing laboratories. This expansion facilitates greater access to biomarker testing services, including it, for patients nationwide. Patients visiting hospitals for cancer treatment may undergo biomarker testing to determine their eligibility for targeted therapies such as these, leading to increased demand for biomarker testing services.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The China market dominated the Asia Pacific PARP Inhibitor Biomarkers Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $109.1 Million by 2031. The Japan market is registering a CAGR of 8.2% during (2024 - 2031). Additionally, The India market would showcase a CAGR of 9.6% during (2024 - 2031).
The adoption of this in clinical practice and research settings has been steadily increasing, driven by several factors that highlight their importance in personalized cancer care and precision medicine. For example, clinical practice guidelines from reputable organizations, such as the National Comprehensive Cancer Network (NCCN).
Additionally, the market is witnessing several notable trends that reflect the evolving landscape of precision oncology and personalized cancer care. These trends encompass advancements in biomarker discovery, technological innovations in biomarker testing, shifts in clinical practice guidelines, and the emergence of novel therapeutic strategies.
As the hospital sector in India expands, there is increased access to healthcare services, including diagnostic facilities and specialized testing laboratories. This expansion facilitates greater access to biomarker testing services, including it, for patients nationwide. Patients visiting hospitals for cancer treatment may undergo biomarker testing to determine their eligibility for targeted therapies such as these, leading to increased demand for biomarker testing services.
Based on Product, the market is segmented into Kits, and Assays. Based on Application, the market is segmented into Breast Cancer, Ovarian Cancer, and Others. Based on Services, the market is segmented into BRCA 1 & 2 Testing, HRD Testing, HRR Testing, and Others.Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
List of Key Companies Profiled
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Market Report Segmentation
By Product- Kits
- Assays
- Breast Cancer
- Ovarian Cancer
- Others
- BRCA 1 & 2 Testing
- HRD Testing
- HRR Testing
- Others
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Asia Pacific PARP Inhibitor Biomarkers Market by Product
Chapter 5. Asia Pacific PARP Inhibitor Biomarkers Market by Application
Chapter 6. Asia Pacific PARP Inhibitor Biomarkers Market by Services
Chapter 7. Asia Pacific PARP Inhibitor Biomarkers Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Myriad Genetics, Inc.
- Thermo Fisher Scientific, Inc.
- Illumina, Inc.
- NeoGenomics Laboratories
- Qiagen N.V
- Agilent Technologies, Inc.
- Merck KGaA
- Bayer AG
- AstraZeneca PLC
- GlaxoSmithKline PLC (GSK)
Methodology
LOADING...
